Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XPF-002 · TV-45070, XEN-401-S

Small molecule · developed by Xenon Pharmaceuticals

Phase 1/2 Most advanced trial (none active)
XENE Developer
1 Registered trials

What is XPF-002?

XPF-002 (also called XEN402) is a topical ointment applied to the skin twice daily. It has been studied in primary and inherited erythromelalgia, a rare disorder of painful, burning skin flushing in the extremities.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
TV-45070, XEN-401-S, XEN-402
Drug type
Small molecule
Therapy area
Cardiovascular
Developer
Xenon Pharmaceuticals Inc. (XENE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
A5595LHJ2L

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01486446 Phase 1/2 Primary Erythromelalgia Completed XENE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Inherited ErythromelalgiaPrimary Erythromelalgia

More from Xenon Pharmaceuticals

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XENE page.

Follow XENE, the company behind XPF-002

See XENE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XENE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.